Halliburton director reports restricted stock activity and share holdings. A Halliburton Co. director filed a Form 4 reporting equity compensation-related transactions on 12/05/2025. The director acquired 7,485 restricted stock units at an exercise price of $0, each representing one share of Halliburton common stock. On the same date, 6,092 restricted stock units granted on December 5, 2024 vested, resulting in the acquisition of 6,092 shares of common stock at $0.
Following these transactions, the director beneficially owns 580,688.509 shares of Halliburton common stock directly and 7,485 restricted stock units that each convert into one share. The filing notes that these restricted stock units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if elected, after the director leaves the board.
Halliburton Company reported an equity award to one of its directors on a Form 4. On 12/05/2025, the director acquired 7,485 restricted stock units (RSUs) tied to Halliburton common stock at an exercise price of $0, classified as an acquisition transaction. Each RSU represents a right to receive one share of common stock.
The RSUs from the 12/2025 grant vest in one year on the first anniversary of the award, with shares delivered either at vesting or, if the director elected deferral, after ceasing service as a director. The filing also shows previously granted RSUs from 12/2024 and 12/2023, with 6,226.77 and 5,040.19 underlying shares, respectively, including dividend equivalent units through September 30, 2025. Following the reported transactions, the RSUs are held in direct ownership.
Halliburton Company director reported equity awards and vesting activity dated 12/05/2025. The director acquired 7,485 restricted stock units (RSUs) labeled as "12/2025 Restricted Stock Units," each representing a right to receive one share of common stock. On the same date, 6,092 RSUs granted December 5, 2024 vested, resulting in the acquisition of 6,092 shares of common stock at a stated price of $0.
After these transactions, the director beneficially owned 16,643 shares of common stock directly. Additional RSU positions remain outstanding from prior annual grants, including blocks labeled as "12/2022" and "12/2021 Restricted Stock Units" that incorporate dividend equivalent units through September 30, 2025. The RSUs generally vest in one year on the first anniversary of the award, with shares delivered upon vesting or after service as a director if deferral was elected.
Halliburton Company director Form 4 details equity changes. On 12/05/2025, the director reported a disposition of 16,000 shares of Halliburton common stock. The filing also shows a new grant of 12/2025 restricted stock units covering 7,485 shares of common stock, reported as derivative securities.
Each restricted stock unit represents a right to receive one share of Halliburton common stock. The 12/2025 units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if the director elected to defer, after ceasing board service. The director also lists multiple outstanding restricted stock unit awards from 2016 through 2024, including dividend equivalent units through September 30, 2025.
Halliburton Company reported a new equity award for one of its directors. On December 5, 2025, the director acquired 7,485 restricted stock units (RSUs) tied to Halliburton common stock at a stated price of $0 per unit. Each RSU represents the right to receive one share of Halliburton common stock.
The 12/2025 RSUs vest in one year on the first anniversary of the award, with shares delivered either at vesting or, if the director elected deferral, after they cease serving as a director. The filing also lists multiple prior RSU grants and 19,310.229 stock equivalent units that convert into common stock on a one-for-one basis and are settled in shares following cessation as a director.
Halliburton Company director equity update: A Halliburton Co (HAL) director reported receiving 7,485 restricted stock units on 12/05/2025 at a price of $0, reflecting an equity award rather than an open‑market purchase. Each restricted stock unit represents the right to receive one share of Halliburton common stock.
The newly granted 12/2025 restricted stock units vest in one year on the first anniversary of the award, with shares delivered either upon vesting or, if the director elected to defer receipt, after cessation as a director. The director also beneficially owns multiple prior‑year restricted stock unit awards and stock equivalent units, including 6,226.77 units from 12/2024, 13,438.45 units from 12/2020, and 41,930.748 stock equivalent units accrued under the Directors' Deferred Compensation Plan, all convertible into common stock on a one‑for‑one basis, generally following cessation as a director.
Halliburton Company’s director, president and CEO reported routine changes in ownership tied to equity compensation. On December 4, 2025, 20,966 shares of common stock were transferred to Halliburton to cover federal tax withholding when restricted stock vested from a grant originally made on December 2, 2020. The reference price for the tax withholding was $26.91 per share, the NYSE closing price on December 2, 2025.
After this transaction, the insider beneficially owns 997,632.02 shares of Halliburton common stock, including 901.551 shares purchased through the company’s employee stock purchase plan for the period ending March 31, 2025. The filing also lists several outstanding stock options with exercise prices between $31.44 and $53.54, and notes that a 99,200-share option grant that was due to expire on December 2, 2025 has now expired.
Halliburton Company executive share transaction disclosed
A Halliburton Company officer, identified as President - Western Hemisphere, reported a routine share transaction dated December 4, 2025. The filing shows that 7,383 shares of common stock were transferred back to Halliburton to cover federal tax withholding triggered by the vesting of previously granted stock under the company’s Stock and Incentive Plan. The closing price of Halliburton common stock on the New York Stock Exchange on December 2, 2025, when the stock vested, was $26.91.
After this tax-related share transfer, the officer beneficially owned 444,990.607 shares of Halliburton common stock. The report also lists several outstanding stock options to buy Halliburton common stock with exercise prices between $27.14 and $55.68 and expiration dates ranging from January 4, 2026 to December 20, 2028, indicating existing long-term equity incentives.
Halliburton Company executive Sarah I. Rubenfeld, EVP Administration & CHRO, reported routine equity transactions involving Halliburton common stock. On December 4, 2025, 5,840 shares of common stock were transferred to Halliburton to cover federal tax withholding when restricted stock vested under the Stock and Incentive Plan. The vesting relates to stock granted on December 2, 2020, using the New York Stock Exchange closing price of $26.91 on December 2, 2025 for tax purposes. After these tax-related shares were withheld, she beneficially owned 484,831.685 shares directly, including 929.708 shares acquired through the Employee Stock Purchase Plan.
The filing also lists several outstanding stock options, including options to buy 51,100, 34,300, and 30,500 shares at exercise prices of $31.44, $43.38, and $53.54, respectively, with expirations in 2028, 2027, and 2026. A separate option for 44,500 shares at an exercise price of $38.95 expired unexercised on December 2, 2025.
Halliburton Company officer reports tax-related share transfer and option expiration. A Senior Vice President and Treasurer of Halliburton Company reported a Form 4 transaction dated December 4, 2025. The filing shows 658 shares of common stock were transferred to Halliburton to cover federal tax withholding when restrictions lapsed on stock granted under the company’s Stock and Incentive Plan, based on a New York Stock Exchange closing price of $26.91 on December 2, 2025. After this transaction, the officer beneficially owns 77,126 shares of common stock directly. The report also lists several outstanding stock options and notes that an option covering 8,300 shares, originally granted on December 2, 2015, expired on December 2, 2025.